Mirum Q3 net product sales $90.3M (+89% YoY); raises FY 2024 guidance to $330-335M

Mirum Pharmaceuticals, Inc.

2024-Q3 EPS reported -$1.36 revenue$237,474,000

LIVMARLI net sales $59.1M; CHOLBAM/CHENODAL combined $31.2M.
Cash & investments $293.8M vs $286.3M at Dec 2023; OpEx $103.1M incl $18M non-cash.
PDUFA date for chenodiol in CTX set for Dec 28, 2024.
Volixibat granted breakthrough therapy designation for PBC; interim data at AASLD.
In-licensed PDE4D inhibitor MRM-3379 for Fragile X syndrome; Phase 2 expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.